Amneal Says Fed. Circ. Redo In Drug Patent Row Unnecessary

By Steven Trader (April 19, 2018, 8:03 PM EDT) -- Amneal Pharmaceuticals urged the Federal Circuit on Wednesday to deny Merck & Co.'s request for reconsideration, or full rehearing, of a panel's decision affirming that a generic nasal spray Amneal sells doesn't infringe one of Merck's patents, contesting the theory that the ruling was based on analysis of the wrong drug sample....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!